Evaluating Serum Calprotectin and Serum Oncostatin M Levels as Diagnostic Markers in Crohn's Disease and Ulcerative Colitis Iraqi Patients. Research

Yahya G. Karwi; Inam S. Arif; Shaymaa A. Abdulameer

doi:10.32947/ajps.v24i2.1067

Authors

Yahya G. Karwi Clinical Pharmacy Department/ College of Pharmacy/ Mustansiriyah University
Inam S. Arif College of Pharmacy; Mustansiriyah University, Baghdad, Iraq
Shaymaa A. Abdulameer Faculty of Pharmacy, Al-Turath University College, Baghdad, Iraq

DOI:

https://doi.org/10.32947/ajps.v24i2.1067

Keywords:

Inflammatory bowel disease, Crohn's disease, ulcerative colitis, serum calprotectin, serum oncostatin M

Abstract

Abstract

Introduction: Inflammatory bowel disease (IBD), comprising Crohn's disease (CD) and ulcerative colitis (UC), presents as chronic gastrointestinal inflammation. Timely diagnosis and effective monitoring are crucial for better outcomes. This study aims to explore serum calprotectin and oncostatin M as potential biomarkers for diagnosing and monitoring CD and UC. Calprotectin, released during inflammation, and oncostatin M, an immune-response cytokine, have shown promise, but their precise role in IBD remains unclear.

Methodology: Using a cross-sectional observational design, the study included 93 IBD patients on biological treatment (50 CD, 43 UC) at Baghdad Teaching Hospital. Demographic data and disease characteristics were collected via interviews, and blood samples were analyzed using specific ELISA kits for calprotectin and oncostatin M levels.

Results: The results demonstrated significantly elevated serum levels of both biomarkers in IBD patients, increasing with disease activity. Significant distinctions were observed among different disease statuses in UC and CD patients.

Conclusion: These findings suggest that serum calprotectin and oncostatin M have potential as practical and non-invasive biomarkers for diagnosing and monitoring IBD. However, further research is required to validate their clinical utility and optimize IBD management.

References

- Guan Q. A Comprehensive Review and Update on the Pathogenesis of Inflammatory Bowel Disease. J Immunol Res. 2019;2019:7247238. DOI: https://doi.org/10.1155/2019/7247238

- Roda G, Chien Ng S, Kotze PG, Argollo M, Panaccione R, Spinelli A, et al. Crohn's disease. Nat Rev Dis Primers. 2020;6(1):22. DOI: https://doi.org/10.1038/s41572-020-0156-2

- Gajendran M, Loganathan P, Jimenez G, Catinella AP, Ng N, Umapathy C, et al. A comprehensive review and update on ulcerative colitis(). Dis Mon. 2019;65(12):100851. DOI: https://doi.org/10.1016/j.disamonth.2019.02.004

- Seyed Tabib NS, Madgwick M, Sudhakar P, Verstockt B, Korcsmaros T, Vermeire S. Big data in IBD: big progress for clinical practice. Gut. 2020;69(8):1520-32. DOI: https://doi.org/10.1136/gutjnl-2019-320065

- Seyedian SS, Nokhostin F, Malamir MD. A review of the diagnosis, prevention, and treatment methods of inflammatory bowel disease. J Med Life. 2019;12(2):113-22. DOI: https://doi.org/10.25122/jml-2018-0075

- Muzammil MA, Fariha F, Patel T, Sohail R, Kumar M, Khan E, et al. Advancements in Inflammatory Bowel Disease: A Narrative Review of Diagnostics, Management, Epidemiology, Prevalence, Patient Outcomes, Quality of Life, and Clinical Presentation. Cureus. 2023;15(6):e41120. DOI: https://doi.org/10.7759/cureus.41120

- Arif IS, Kamal YM, Raoof IB. Nrf2 as a modulator of oxidative stress. Al Mustansiriyah Journal of Pharmaceutical Sciences. 2021;21(4):17-23. DOI: https://doi.org/10.32947/ajps.v21i4.798

- Kasim AAH, Mohammed MM. Biochemical Evaluation of Some Liver Enzymes in Type 2 Diabetes Mellitus Iraqi Patients. Al Mustansiriyah Journal of Pharmaceutical Sciences. 2012;12(2):107-14. DOI: https://doi.org/10.32947/ajps.v12i2.256

- Noor NM, Sousa P, Paul S, Roblin X. Early Diagnosis, Early Stratification, and Early Intervention to Deliver Precision Medicine in IBD. Inflamm Bowel Dis. 2022;28(8):1254-64. DOI: https://doi.org/10.1093/ibd/izab228

- Ruggeri SY, Emerson A, Russell CL. A concept analysis of routines for improving health behaviors. International Journal of Nursing Sciences. 2023. DOI: https://doi.org/10.1016/j.ijnss.2023.06.004

- Mori A, Mitsuyama K, Sakemi R, Yoshioka S, Fukunaga S, Kuwaki K, et al. Evaluation of serum calprotectin levels in patients with inflammatory bowel disease. The Kurume medical journal. 2019;66(4):209-15. DOI: https://doi.org/10.2739/kurumemedj.MS664009

- Azramezani Kopi T, Shahrokh S, Mirzaei S, Asadzadeh Aghdaei H, Amini Kadijani A. The role of serum calprotectin as a novel biomarker in inflammatory bowel diseases: a review study. Gastroenterol Hepatol Bed Bench. 2019;12(3):183-9.

- Cao Y, Dai Y, Zhang L, Wang D, Yu Q, Hu W, et al. Serum oncostatin M is a potential biomarker of disease activity and infliximab response in inflammatory bowel disease measured by chemiluminescence immunoassay. Clin Biochem. 2022;100:35-41. DOI: https://doi.org/10.1016/j.clinbiochem.2021.11.011

- Bertani L, Fornai M, Fornili M, Antonioli L, Benvenuti L, Tapete G, et al. Serum oncostatin M at baseline predicts mucosal healing in Crohn's disease patients treated with infliximab. Aliment Pharmacol Ther. 2020;52(2):284-91. DOI: https://doi.org/10.1111/apt.15870

- Cuschieri S. The STROBE guidelines. Saudi J Anaesth. 2019;13(Suppl 1):S31-S4. DOI: https://doi.org/10.4103/sja.SJA_543_18

- von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet (London, England). 2007;370(9596):1453-7. DOI: https://doi.org/10.1016/S0140-6736(07)61602-X

- Jukic A, Bakiri L, Wagner EF, Tilg H, Adolph TE. Calprotectin: from biomarker to biological function. Gut. 2021;70(10):1978-88. DOI: https://doi.org/10.1136/gutjnl-2021-324855